Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Journal: EJHaem
Published: November 05, 2021
Primary Gastric Choriocarcinoma: A Case Report of Early Successful Treatment Outcome.
Journal: JCO oncology practice
Published: May 05, 2020
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Journal: British journal of haematology
Published: April 04, 2018
Acute myeloid leukemia with t(4;12)(q12;p13) treated with an allogeneic stem cell transplant: A case report and review of the literature.
Journal: Leukemia research reports
Published: February 05, 2018
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Journal: British journal of haematology
Published: May 17, 2017
E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.
Journal: The oncologist
Published: March 08, 2017
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Journal: British journal of haematology
Published: June 02, 2016
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
Journal: Blood
Published: August 19, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026